X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1368) 1368
Book Review (370) 370
Publication (108) 108
Newsletter (14) 14
Book Chapter (7) 7
Magazine Article (6) 6
Conference Proceeding (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1180) 1180
bosentan (1097) 1097
humans (1009) 1009
hypertension, pulmonary - drug therapy (612) 612
male (592) 592
female (519) 519
pulmonary hypertension (519) 519
antihypertensive agents - therapeutic use (416) 416
sulfonamides - therapeutic use (400) 400
middle aged (385) 385
treatment outcome (351) 351
endothelin (342) 342
adult (333) 333
cardiac & cardiovascular systems (333) 333
endothelin receptor antagonists (322) 322
therapy (321) 321
pulmonary arterial hypertension (301) 301
hypertension, pulmonary - physiopathology (298) 298
sildenafil (292) 292
hypertension (281) 281
pharmacology & pharmacy (277) 277
respiratory system (269) 269
animals (265) 265
survival (259) 259
double-blind (210) 210
aged (196) 196
arterial-hypertension (193) 193
abridged index medicus (184) 184
drug therapy (182) 182
hypertension, pulmonary - etiology (174) 174
care and treatment (155) 155
bosentan therapy (152) 152
drug therapy, combination (149) 149
rats (149) 149
vasodilator agents - therapeutic use (144) 144
prostacyclin (142) 142
pulmonary arterial-hypertension (139) 139
medicine, general & internal (137) 137
hypertension, pulmonary - diagnosis (133) 133
research (133) 133
endothelin receptor antagonist (132) 132
sildenafil citrate (131) 131
sulfonamides - pharmacology (131) 131
epoprostenol (127) 127
disease (126) 126
inhaled iloprost (124) 124
scleroderma (116) 116
antihypertensive agents - administration & dosage (113) 113
hemodynamics (112) 112
medicine & public health (109) 109
retrospective studies (107) 107
diagnosis (106) 106
hypertension, pulmonary - mortality (106) 106
sulfonamides - administration & dosage (106) 106
endothelin-1 (105) 105
receptor antagonist bosentan (104) 104
analysis (103) 103
familial primary pulmonary hypertension (103) 103
time factors (102) 102
endothelin-receptor antagonist (101) 101
piperazines - therapeutic use (100) 100
mortality (99) 99
antihypertensive agents - adverse effects (93) 93
follow-up studies (93) 93
adolescent (92) 92
rheumatology (92) 92
epoprostenol - therapeutic use (91) 91
ambrisentan (89) 89
risk factors (89) 89
treprostinil (89) 89
health aspects (88) 88
prognosis (88) 88
child (87) 87
systemic sclerosis (87) 87
expression (86) 86
iloprost (86) 86
pulmonary arteries (84) 84
dosage and administration (83) 83
placebo-controlled trial (83) 83
scleroderma, systemic - complications (83) 83
cardiovascular (82) 82
administration, oral (81) 81
nitric-oxide (81) 81
prospective studies (81) 81
hypertension, pulmonary - therapy (80) 80
combination therapy (79) 79
dose-response relationship, drug (79) 79
continuous intravenous epoprostenol (78) 78
efficacy (78) 78
pharmacokinetics (77) 77
hypertension, pulmonary - complications (75) 75
purines - therapeutic use (75) 75
sulfonamides - adverse effects (75) 75
sulfones - therapeutic use (75) 75
antihypertensive agents - pharmacology (72) 72
prostacyclin analog (72) 72
clinical trials (71) 71
hemodynamics - drug effects (71) 71
sitaxsentan (71) 71
young adult (71) 71
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1338) 1338
Spanish (16) 16
French (12) 12
German (10) 10
Russian (6) 6
Turkish (5) 5
Korean (2) 2
Polish (2) 2
Portuguese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 142, Issue 6, pp. 1383 - 1390
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 834 - 844
Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a... 
INHALED ILOPROST | SURVIVAL | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | EPOPROSTENOL | COMBINATION THERAPY | HEART-FAILURE | DOUBLE-BLIND | BOSENTAN | Hypertension, Pulmonary - mortality | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Hypertension, Pulmonary - physiopathology | Male | Hospitalization | Disease Progression | Tadalafil | Phenylpropionates - therapeutic use | Peptide Fragments - blood | Adult | Female | Phenylpropionates - adverse effects | Aged | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Natriuretic Peptide, Brain - blood | Pyridazines - adverse effects | Pyridazines - therapeutic use | Symptomatology | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Pulmonary hypertension | Ambrisentan | Hypertension | Edema | Brain natriuretic peptide | Headache | Functional morphology | Pulmonary arteries | Lung diseases | Drug therapy | Patients | Clinical outcomes | Index Medicus | Abridged Index Medicus | Drug side effects | Assaigs clínics de medicaments | Efectes secundaris dels medicaments | Hipertensió pulmonar | Drug testing | Life Sciences | Human health and pathology | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 21, pp. 1968 - 1977
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 809 - 818
Journal Article
Journal Article
Chest, ISSN 0012-3692, 01/2009, Volume 135, Issue 1, pp. 122 - 129
Some endothelin receptor antagonists (ERAs) are associated with liver function test (LFT) result abnormalities. However, ambrisentan has an incidence of serum... 
bosentan | sulfonamide | ambrisentan | hepatotoxicity | propanoic acid | pulmonary hypertension | sitaxsentan | serum aminotransferase | endothelin receptor antagonist | liver function test | Liver function test | Bosentan | Sulfonamide | Endothelin receptor antagonist | Serum aminotransferase | Hepatotoxicity | Propanoic acid | Pulmonary hypertension | Ambrisentan | Sitaxsentan | SURVIVAL | CONTROLLED-TRIAL | EFFICACY | ATRASENTAN | SAFETY | ENDOTHELIN ANTAGONIST BOSENTAN | RECEPTOR ANTAGONIST | REFRACTORY PROSTATE-CANCER | RESPIRATORY SYSTEM | MEN | BLOCKADE | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Male | Young Adult | Phenylpropionates - therapeutic use | Adult | Female | Hypertension, Pulmonary - drug therapy | Child | Endothelin Receptor Antagonists | Hypertension, Pulmonary - enzymology | Pyridazines - therapeutic use | Liver Function Tests | Treatment Outcome | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Disease-Free Survival | Sulfonamides - therapeutic use | Adolescent | Sulfonamides - adverse effects | Transaminases - blood | Aged | Isoxazoles - therapeutic use | Isoxazoles - adverse effects | Complications and side effects | Analysis | Dosage and administration | Research | Drug therapy | Liver function tests | Index Medicus | Abridged Index Medicus
Journal Article